Research ExplorerPublicationsPharmacokinetics of oral doses of telmisartan and nisoldipin...

Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.

Standard

Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. / Bajcetic, Milica; Benndorf, Ralf; Appel, Daniel; Schwedhelm, Edzard; Schulze, Friedrich; Riekhof, Daniel; Maas, Renke; Böger, Rainer.

In: J CLIN PHARMACOL, Vol. 47, No. 3, 3, 2007, p. 295-304.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bajcetic, M, Benndorf, R, Appel, D, Schwedhelm, E, Schulze, F, Riekhof, D, Maas, R & Böger, R 2007, 'Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.', J CLIN PHARMACOL, vol. 47, no. 3, 3, pp. 295-304. <http://www.ncbi.nlm.nih.gov/pubmed/17322141?dopt=Citation>

APA

Bajcetic, M., Benndorf, R., Appel, D., Schwedhelm, E., Schulze, F., Riekhof, D., Maas, R., & Böger, R. (2007). Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J CLIN PHARMACOL, 47(3), 295-304. [3]. http://www.ncbi.nlm.nih.gov/pubmed/17322141?dopt=Citation

Vancouver

Bajcetic M, Benndorf R, Appel D, Schwedhelm E, Schulze F, Riekhof D et al. Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J CLIN PHARMACOL. 2007;47(3):295-304. 3.

Bibtex

@article{ee4d6c0411134d2a92802e2e246e255f,
title = "Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.",
abstract = "This randomized, single-blind, parallel-group study was performed to assess pharmacokinetic interactions potentially occurring during concomitant use of telmisartan and nisoldipine. Patients with essential hypertension (n = 37) were treated with once-daily doses of telmisartan, nisoldipine, or their combination for 6 weeks. The regimen was started at low dose with an increase of dosage after 3 weeks of treatment. AUC(ss) (132%; P <.01) of telmisartan applied in doses of 80 mg was significantly higher after concomitant application with nisoldipine (10 mg), whereas CL/f(ss) (-54%; P <.05) and Vz/f(ss) (-72%; P <.05) were significantly lower. Regarding pharmacokinetic parameters of nisoldipine, significant differences between treatment groups were not detected. In conclusion, the results of this study strongly suggest that concomitant treatment with nisoldipine enhances telmisartan bioavailability in hypertensive individuals. Larger crossover trials will have to establish these observations and investigate whether interaction of both drugs affects telmisartan efficacy and tolerability in clinical use.",
author = "Milica Bajcetic and Ralf Benndorf and Daniel Appel and Edzard Schwedhelm and Friedrich Schulze and Daniel Riekhof and Renke Maas and Rainer B{\"o}ger",
year = "2007",
language = "Deutsch",
volume = "47",
pages = "295--304",
journal = "J CLIN PHARMACOL",
issn = "0091-2700",
publisher = "SAGE Publications",
number = "3",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.

AU - Bajcetic, Milica

AU - Benndorf, Ralf

AU - Appel, Daniel

AU - Schwedhelm, Edzard

AU - Schulze, Friedrich

AU - Riekhof, Daniel

AU - Maas, Renke

AU - Böger, Rainer

PY - 2007

Y1 - 2007

N2 - This randomized, single-blind, parallel-group study was performed to assess pharmacokinetic interactions potentially occurring during concomitant use of telmisartan and nisoldipine. Patients with essential hypertension (n = 37) were treated with once-daily doses of telmisartan, nisoldipine, or their combination for 6 weeks. The regimen was started at low dose with an increase of dosage after 3 weeks of treatment. AUC(ss) (132%; P <.01) of telmisartan applied in doses of 80 mg was significantly higher after concomitant application with nisoldipine (10 mg), whereas CL/f(ss) (-54%; P <.05) and Vz/f(ss) (-72%; P <.05) were significantly lower. Regarding pharmacokinetic parameters of nisoldipine, significant differences between treatment groups were not detected. In conclusion, the results of this study strongly suggest that concomitant treatment with nisoldipine enhances telmisartan bioavailability in hypertensive individuals. Larger crossover trials will have to establish these observations and investigate whether interaction of both drugs affects telmisartan efficacy and tolerability in clinical use.

AB - This randomized, single-blind, parallel-group study was performed to assess pharmacokinetic interactions potentially occurring during concomitant use of telmisartan and nisoldipine. Patients with essential hypertension (n = 37) were treated with once-daily doses of telmisartan, nisoldipine, or their combination for 6 weeks. The regimen was started at low dose with an increase of dosage after 3 weeks of treatment. AUC(ss) (132%; P <.01) of telmisartan applied in doses of 80 mg was significantly higher after concomitant application with nisoldipine (10 mg), whereas CL/f(ss) (-54%; P <.05) and Vz/f(ss) (-72%; P <.05) were significantly lower. Regarding pharmacokinetic parameters of nisoldipine, significant differences between treatment groups were not detected. In conclusion, the results of this study strongly suggest that concomitant treatment with nisoldipine enhances telmisartan bioavailability in hypertensive individuals. Larger crossover trials will have to establish these observations and investigate whether interaction of both drugs affects telmisartan efficacy and tolerability in clinical use.

M3 - SCORING: Zeitschriftenaufsatz

VL - 47

SP - 295

EP - 304

JO - J CLIN PHARMACOL

JF - J CLIN PHARMACOL

SN - 0091-2700

IS - 3

M1 - 3

ER -